COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02530320
Recruitment Status : Completed
First Posted : August 21, 2015
Last Update Posted : April 2, 2020
Information provided by (Responsible Party):
Grupo Español de Investigación en Neurooncología

Brief Summary:
This multicenter, open-label, phase II trial aims to assess the safety and efficacy of palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic with the activity of the protein RB preserved.

Condition or disease Intervention/treatment Phase
Oligodendroglioma Oligoastrocytoma Drug: Palbociclib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Actual Study Start Date : October 25, 2015
Actual Primary Completion Date : December 2019
Actual Study Completion Date : March 2020

Arm Intervention/treatment
Experimental: Palbociclib (PD0332991)
Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
Drug: Palbociclib
Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
Other Name: PD0332991

Primary Outcome Measures :
  1. Progression-free survival (PFS) at six months (PFS6m) [ Time Frame: 6 months ]
    Percentage of patients who have progressed / no progress after 6 months of treatment

Secondary Outcome Measures :
  1. Safety and tolerability of oral administration of PD0332991 (reported adverse events, physical examinations and laboratory tests. Toxicity will be classified and tabulated by NCI-CTCAE v 4.0.) [ Time Frame: Three years ]
    Type, incidence, severity, frequency, severity and relationship with IMP of reported adverse events, physical examinations and laboratory tests. Toxicity will be classified and tabulated by NCI-CTCAE v 4.0.

  2. Anti-tumor response according to RANO criteria [ Time Frame: 30 months ]
    According to RANO criteria, assessed by the PI of each center. There will be a central review.

  3. Overall survival (OS) [ Time Frame: 30 months ]
    Time from randomization to death by any cause.

  4. Response duration [ Time Frame: 30 months ]
    Time from first objective response up to disease progression according RANO (in patients with objective responses).

  5. Changes in the use of glucocorticoids [ Time Frame: 30 months ]
    Percentage of patients decreasing doses of corticosteroids during treatment.

  6. Changes in neurological status. [ Time Frame: 30 months ]
    By means of minimental test, it will be determined the changes in neurological status of patients.

  7. Tumor biomarkers assessment [ Time Frame: 30 months ]
    It will be evaluated whether some biomarkers are related with the Progression Free Survival/Overall survival and response rates. The following biomarkers will be assessed: Deletions in CDKN2A, CDKN2B, 1p, 19q; mutations in IDH, amplifications in CDK4, CDK6, cyclin D.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ability to understand and sign the informed consent approved by the Ethic Committee.
  2. Men or women aged greater than or equal to 18.
  3. Patients with oligodendroglioma anaplastic or oligoastrocytoma anaplastic according to WHO classification and histologically confirmed. Note: It can be included patients with oligoastrocytoma or oligodendroglioma G2 only if they have suffered a recurrence in which the diagnosis of the resection were G3.
  4. Patients in relapse after radiotherapy and one or two lines of chemotherapy. Note: Both previous radiotherapy and chemotherapy could be received in adjuvant therapy or previous recurrences. It is also accepted to be received concurrent chemoradiotherapy. In the secondary oligodendrogliomas or oligoastrocytomas anaplastic, the patients could have received chemotherapy and radiotherapy when the tumor was G2.
  5. All patients have to present positivity in immunohistochemical study for the RB protein in the tumor samples sent to the central lab.
  6. The cases must have 10 slides or a tumor block available from a biopsy or surgery.
  7. All patients have to show disease progression in a cerebral nuclear magnetic resonance.
  8. Interval of at least one week between the previous intracranial biopsy and the inclusion.
  9. Interval of at least 12 weeks between radiotherapy and the inclusion, unless: a) Recurrent tumor confirmed histologically b) recurrency showed in the NMR out of radiotherapy.
  10. Patients should have been recovered from previous therapies: 28 days since the end of any investigational product and since the end of any cytotoxic treatment.
  11. ECOG≤2
  12. Stable or decreasing dose of corticoids during the five days prior to the inclusion
  13. patients who have been suffered from a tumor resection in the last recurrence are eligible if:

    • A good surgery recover
    • there is a measurable or evaluable disease after surgery
  14. Good bone marrow function:

    • Neutrophils ≥ 1500/mm3 (1.5x10e9/L)
    • Platelet ≥ 100.000/mm3 (100 x 10e9)
    • Hemoglobin ≥ 9 g/dL
    • Seric creatinine ≤ 1.5 x LSN of the site or estimated clearance ≥ 60 ml/min calculated.
    • Bilirubin ≤ 1.5 x LSN (if Gilbert's syndrome ≤ 3 xLSN) AST (SGOT) and/or ALT ≤ 3 x LSN; alkaline phosphatase ≤ 2.5 x LSN.
  15. Nor pregnant women nor breast-feeding women. Women with heterosexual activity should have a negative pregnant test before the inclusion in the study. Both women and men should use an accepted contraceptive method during the study treatment and 1 month after treatment completed.

Exclusion Criteria:

  1. Presence of meningeal carcinomatosis disseminated.
  2. Concomitant treatment with other investigational products
  3. Previous treatment wih an investigational product that could be active for CDK4/6
  4. Any kind of surgery in the previous 2 weeks
  5. Presence of any clinically significant gastrointestinal abnormality that can affect oral administration, transit or absorption of study drug, such as the inability to take medication by mouth as tablets.
  6. Presence of any psychiatric or cognitive disorder that limits the understanding or the signature of informed consent and / or jeopardize the fulfillment of the requirements of this protocol.
  7. In the 7 days prior to the beginning of the treatment, to have received a treatment with: - Drugs inhibitor of the CYP3A4 - Drugs inductors of the CYP3A4 - Drugs that extends the QT interval
  8. QTc interval >480 msec, familiar history or personal of QT large Syndrome, QT short Syndrome, Brugada syndrome, QTc extension or Torsade de Pointes history
  9. Electrolyte disorder that may affect the QTc interval
  10. Significant or uncontrolled cardiovascular disease, including:

    • Myocardial infarction within the previous 12 months
    • Uncontrolled angina within the previous 6 months
    • Congestive heart failure in the previous 6 months
    • History of clinically significant ventricular arrhythmias of any type (as ventricular tachycardia, ventricular fibrillation or torsades de pointes)
    • History of second or third grade heart block (these patients may be eligible if you currently have a pacemaker)
    • Ictus
    • Pulmonary embolism
  11. History of any cancer, except for the following circumstances:

    • Patients with a history of other malignancies are eligible if they have been free of disease for at least the last 3 years, and at the discretion of the investigator, there is low risk of disease recurrence.
    • Patients with the following cancers are eligible even if they are diagnosed and treated in the last 3 years: carcinoma in situ of the cervix and basal cell or basal cell skin carcinoma. Patients are ineligible if there is evidence of any neoplastic disease that required therapy other than surgery in the past 3 years.
  12. Patients positive for HIV
  13. Inflammatory bowel disease, chronic diarrhea, short gut syndrome or any upper gastrointestinal surgery including gastric resection.
  14. History of allergic reactions to Palbociclib
  15. Another acute or chronic serious medical condition, uncontrolled intercurrent illness or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of test results and that,investigator's discretion, make the patient inappropriate for entry into this trial. Uncontrolled intercurrent illness including, but are not limited to, ongoing or active infection or psychiatric illness / social situations that limit the compliance of study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02530320

Layout table for location information
Hospital Insular de Canarias
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Son Espases
Palma de Mallorca, Mallorca, Spain
Consorcio Hospitalario Provincial de Castellón
Castello de la Plana, Valencia, Spain
Hospital Clínic de Barcelona
Barcelona, Spain
ICO Hospitalet
Barcelona, Spain
Hospital de León
León, Spain
Hospital 12 de Octubre
Madrid, Spain
Hospital Ramón y Cajal
Madrid, Spain
Hospital Regional de Málaga
Málaga, Spain
Hospital Virgen del Rocio
Sevilla, Spain
Hospital Universitario y Politécnico La Fe
Valencia, Spain
Sponsors and Collaborators
Grupo Español de Investigación en Neurooncología
Layout table for investigator information
Principal Investigator: Juan Manuel Sepúlveda H. 12 de Octubre
Layout table for additonal information
Responsible Party: Grupo Español de Investigación en Neurooncología Identifier: NCT02530320    
Other Study ID Numbers: GEINO 13
First Posted: August 21, 2015    Key Record Dates
Last Update Posted: April 2, 2020
Last Verified: February 2020
Keywords provided by Grupo Español de Investigación en Neurooncología:
oligoastrocytoma anaplastic
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action